BSX vs. SNN: Boston Scientific vs. Smith & Nephew Stock Comparison

Company Profile

Boston Scientific (BSX) and Smith & Nephew (SNN) are both classified in the Health Care Equipment sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

Boston Scientific (BSX) trades as ordinary local shares, while Smith & Nephew (SNN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Boston Scientific (BSX) at 14.12% and Smith & Nephew (SNN) at 11.85% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

For every dollar of sales, both Boston Scientific (BSX) at 16.62% and Smith & Nephew (SNN) at 10.08% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Boston Scientific (BSX) at 19.05% and Smith & Nephew (SNN) at 14.47% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Boston Scientific (BSX) at 19.87% and Smith & Nephew (SNN) at 6.09% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Boston Scientific (BSX) at 55.20% and Smith & Nephew (SNN) at 52.34% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

Smith & Nephew (SNN) at 2.14 keeps current ratio within its industry’s typical mid-range, while Boston Scientific (BSX) at 1.37 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BSX.

Both Boston Scientific (BSX) at 0.46 and Smith & Nephew (SNN) at 0.73 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Boston Scientific (BSX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a yield of 1.24%, ranking against industry peers normally.

Boston Scientific (BSX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a payout of 53.20%, ranking against industry peers normally.

Dividend Metrics

Valuation

Boston Scientific (BSX) at 18.04 sits in the cheaper P/E ratio quartile, while Smith & Nephew (SNN) at 21.19 is closer to its industry’s usual earnings multiple — a discount for BSX, though growth and earnings durability still matter.

On P/S ratio, both Boston Scientific (BSX) at 2.94 and Smith & Nephew (SNN) at 2.07 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Boston Scientific (BSX) at 2.42 sits near its industry’s typical P/B ratio, while Smith & Nephew (SNN) at 12.80 prices above its benchmark range — SNN looks rich relative to book.

Valuation Metrics